Changes to UC Alternative Retirement Plan (ARP) and 403(b)
Plans will be effective on Oct. 1, 2020
The Investment Election window opened on Monday, Aug. 17, and will close on Sept. 19, 2020. Virtual town hall sessions are scheduled over the next few weeks to be held via WebEx. Participants are encouraged to review materials sent to their home as well as attend a WebEx town hall session. An on-demand, recorded version of the WebEx is also available.
As a reminder, the ARP is an offered alternative to the state retirement system (OPERS/STRS), and the university’s 403(b) is available for supplemental retirement plan savings. Changes to the ARP and the 403(b) include reducing the number of approved vendors in order to reduce plan and investment expenses as well as streamlining investment options so that enrollees can better create diversified investment portfolios and track fees.
For more information, refer to the 2020 ARP and 403(b) Retirement Plan Changes page on the Bearcats Landing intranet.
Questions?
Email the UC Benefits team at benefits@uc.edu.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.